GlobeNewswire: Helix BioPharma Corp. Contains the last 10 of 288 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:35:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/07/30/2070795/0/en/Helix-Biopharma-Corp-Announces-Fiscal-Third-Quarter-2020-Results.html?f=22&fvtc=4&fvtv=43534Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results2020-07-30T21:42:00Z<![CDATA[RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2020.]]>https://www.globenewswire.com/news-release/2020/07/13/2061140/0/en/Helix-BioPharma-Corp-Provides-Update-On-The-Timing-Of-Filing-Of-Third-Quarter-Results.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results2020-07-13T11:30:00Z<![CDATA[RICHMOND HILL, Ontario, July 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that, further to its news release dated June 11, 2020, it intends to file its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis (“MD&A”) and related management certifications (the “Interim Disclosure Documents”) by July 30, 2020.]]>https://www.globenewswire.com/news-release/2020/06/26/2053991/0/en/Helix-BioPharma-Corp-to-divest-remaining-ownership-of-Polish-subsidiary.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary2020-06-26T11:30:00Z<![CDATA[RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary (the “Divestment”), Helix Immuno-Oncology S.A. (“HIO”), representing approximately 51% of the issued and outstanding shares of HIO prior to the HIO Private Placement described below.]]>https://www.globenewswire.com/news-release/2020/06/22/2051150/0/en/Helix-BioPharma-Corp-to-Present-at-Proactive-One2One-Virtual-Investor-Forum.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum2020-06-22T11:30:00Z<![CDATA[RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020.]]>https://www.globenewswire.com/news-release/2020/06/11/2047184/0/en/Helix-BioPharma-Corp-Provides-Update-On-The-Timing-Of-Filing-Of-Third-Quarter-Results.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results2020-06-11T21:15:00Z<![CDATA[RICHMOND HILL, Ontario, June 11, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that it intends to rely on exemptions granted in Ontario Instrument 51-505 Temporary Exemption from Certain Corporate Finance Requirements (the “Blanket Relief”) to extend the deadline for filing its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis (“MD&A”) and related management certifications (the “Interim Disclosure Documents”).]]>https://www.globenewswire.com/news-release/2020/05/14/2033412/0/en/Helix-BioPharma-Corp-L-DOS47-Phase-I-Lung-Cancer-Trial-Data-to-be-released-at-ASCO-2020.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 20202020-05-14T11:30:00Z<![CDATA[RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference.]]>https://www.globenewswire.com/news-release/2020/04/02/2010658/0/en/Helix-BioPharma-Corp-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. Provides Corporate Update2020-04-02T11:30:00Z<![CDATA[RICHMOND HILL, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today provides a corporate update.]]>https://www.globenewswire.com/news-release/2020/03/16/2001540/0/en/HELIX-BIOPHARMA-CORP-ANNOUNCES-FISCAL-SECOND-QUARTER-2020-RESULTS.html?f=22&fvtc=4&fvtv=43534HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS2020-03-16T23:51:41Z<![CDATA[RICHMOND HILL, Ontario, March 16, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2020.]]>https://www.globenewswire.com/news-release/2020/03/12/1999948/0/en/Helix-BioPharma-Corp-Closes-6-0-Million-Private-Placement.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. Closes $6.0 Million Private Placement2020-03-12T21:05:00Z<![CDATA[RICHMOND HILL, Ontario, March 12, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 5,042,016 units of the Company (“Units”) at a price of $1.0332 per Unit, and the concurrent disposition of 1,708,023 shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), to a third-party purchaser, representing an 15.5% equity stake in HIO (together with the Units, the “Purchased Securities”), for aggregate gross proceeds of CAD $6,000,000, or $1.19 per Purchased Security.]]>https://www.globenewswire.com/news-release/2020/02/14/1985216/0/en/Helix-BioPharma-Corp-to-Present-at-the-Noble-Capital-Markets-Sixteenth-Annual-Investor-Conference.html?f=22&fvtc=4&fvtv=43534Helix BioPharma Corp. to Present at the Noble Capital Markets’ Sixteenth Annual Investor Conference2020-02-14T12:30:00Z<![CDATA[RICHMOND HILL, Ontario, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting at NobleCon - Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida - on Monday, February 17th at 3:00PM Eastern Standard Time (https://www.nobleconference.com/sixteen#home).]]>